MedPath

A Clinical trial to evaluate the efficacy of Siddha drugs Gandhaga Rasayanam (Internal) & Navanatha sittha thailam (External) in patients having multiple joint pain

Phase 2
Recruiting
Conditions
Patients having arthritis of three or more joints , Patients having RA factor POSITIVE , morning stiffness, CRP positive and anemia.
Registration Number
CTRI/2017/05/008469
Lead Sponsor
Govt siddha medical college
Brief Summary

It is a Non Randomized open clinical trial. During this trial period 500 mg of Gandhaga Rasayanam (Internal) with hot water, twice a day and 10 ml of Navanatha Sittha thailam (External) is administered for 48 days in patients having Uthiravatha suronitham (Rheumatoid arthritis). All the details regarding the study will be documented and the result will be published.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients having arthritis of 3 or more joints 2.
  • Morning stiffness 3.
  • RA factor positive 4.
  • C-Reactive Protein (CRP) positive 5.
  • Anti Cyclic Citrullinated Peptide (Anti CCP) Positive 5.
  • Patients who are willing to undergo laboratory investigations.
Exclusion Criteria
  • Rheumatic fever 2.
  • History of sulphur allergy 3.
  • Psoriatic arthropathica, 4.
  • Progressive systemic sclerosis 5.
  • Gouty arthritis, 6.
  • Pregnancy and lactation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Reduction in pain and swelling and morning stiffness12months
Secondary Outcome Measures
NameTimeMethod
To study the safety parameters of the drug before and after treatment12months

Trial Locations

Locations (1)

Arignar Anna Hospital of Indian Medicine and Homoeopathy

🇮🇳

Chennai, TAMIL NADU, India

Arignar Anna Hospital of Indian Medicine and Homoeopathy
🇮🇳Chennai, TAMIL NADU, India
Dr M Shrisaranya
Principal investigator
8098372738
drshrisaranya@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.